Literature DB >> 8552427

Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations.

E Berry-Kravis1, M Hicar, R Ciurlionis.   

Abstract

The cAMP cascade is an intracellular signal transduction system thought to be important for neuronal regulation and information storage. cAMP production is reduced in platelets from patients with fragile X syndrome. In the present study we assayed cAMP metabolism, Xq27.3 fragile site percentages, size of amplification mutation in fragile X mental retardation-1 gene (FMR-1), and FMR-1 mRNA levels in 21 lymphoblastoid cell lines (LCL) from fragile X patients. cAMP production was diminished in fragile X LCL relative to controls (n = 20) when cells were assayed in prostaglandin E1 (74%, p < 0.02) and in forskolin (64%, p < 0.1) although the difference was statistically significant only in prostaglandin E1. The length of the FMR-1 amplification mutation correlated with measures of cAMP production which were unassociated with receptor activation (r = -0.53, p = 0.02, and r = -0.48, p = 0.03, for unstimulated and forskolin-stimulated cAMP production, respectively). In fragile X LCL, fragile site percentages did not correlate with any measure of cAMP production. All fragile X LCL showed absence of FMR-1 mRNA. These data suggest that diminished cAMP production in fragile X tissues may be linked to the fragile X amplification mutation, either as a result of influences of the mutation on FMR-1 expression or on transcription of other genes downstream from FMR-1.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8552427     DOI: 10.1203/00006450-199511000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  24 in total

1.  Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment.

Authors:  Catherine H Choi; Brian P Schoenfeld; Aaron J Bell; Paul Hinchey; Maria Kollaros; Michael J Gertner; Newton H Woo; Michael R Tranfaglia; Mark F Bear; R Suzanne Zukin; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  Brain Res       Date:  2010-11-12       Impact factor: 3.252

Review 2.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

3.  PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.

Authors:  Catherine H Choi; Brian P Schoenfeld; Eliana D Weisz; Aaron J Bell; Daniel B Chambers; Joseph Hinchey; Richard J Choi; Paul Hinchey; Maria Kollaros; Michael J Gertner; Neal J Ferrick; Allison M Terlizzi; Nicole Yohn; Eric Koenigsberg; David A Liebelt; R Suzanne Zukin; Newton H Woo; Michael R Tranfaglia; Natalia Louneva; Steven E Arnold; Steven J Siegel; Francois V Bolduc; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

4.  Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.

Authors:  Elizabeth M Berry-Kravis; Mark D Harnett; Scott A Reines; Melody A Reese; Lauren E Ethridge; Abigail H Outterson; Claire Michalak; Jeremiah Furman; Mark E Gurney
Journal:  Nat Med       Date:  2021-04-29       Impact factor: 53.440

Review 5.  Fruit flies and intellectual disability.

Authors:  François V Bolduc; Tim Tully
Journal:  Fly (Austin)       Date:  2009-01-12       Impact factor: 2.160

Review 6.  The cyclic AMP phenotype of fragile X and autism.

Authors:  Daniel J Kelley; Anita Bhattacharyya; Garet P Lahvis; Jerry C P Yin; Jim Malter; Richard J Davidson
Journal:  Neurosci Biobehav Rev       Date:  2008-06-17       Impact factor: 8.989

7.  Using Drosophila as a tool to identify Pharmacological Therapies for Fragile X Syndrome.

Authors:  Sean M McBride; Sandra L Holloway; Thomas A Jongens
Journal:  Drug Discov Today Technol       Date:  2012-09-24

8.  Fragile X Mental Retardation Protein positively regulates PKA anchor Rugose and PKA activity to control actin assembly in learning/memory circuitry.

Authors:  James C Sears; Woong Jae Choi; Kendal Broadie
Journal:  Neurobiol Dis       Date:  2019-02-13       Impact factor: 5.996

9.  The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome.

Authors:  Carrie R Jonak; Manbir S Sandhu; Samantha A Assad; Jacqueline A Barbosa; Mahindra Makhija; Devin K Binder
Journal:  Neurotherapeutics       Date:  2021-02-16       Impact factor: 7.620

Review 10.  An "Omic" Overview of Fragile X Syndrome.

Authors:  Olivier Dionne; François Corbin
Journal:  Biology (Basel)       Date:  2021-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.